IQVIA Holdings Inc. $IQV Shares Purchased by Cerity Partners LLC

Cerity Partners LLC increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 12.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 179,675 shares of the medical research company’s stock after acquiring an additional 19,958 shares during the quarter. Cerity Partners LLC owned about 0.11% of IQVIA worth $40,530,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IQV. Eubel Brady & Suttman Asset Management Inc. purchased a new stake in IQVIA during the 3rd quarter worth approximately $14,278,000. Eagle Rock Investment Company LLC increased its stake in IQVIA by 33.6% during the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock worth $8,800,000 after buying an additional 11,657 shares during the period. EDENTREE ASSET MANAGEMENT Ltd purchased a new stake in IQVIA during the 3rd quarter worth approximately $7,368,000. AMG National Trust Bank purchased a new stake in IQVIA during the 3rd quarter worth approximately $3,713,000. Finally, Cornerstone Investment Partners LLC increased its stake in IQVIA by 21.9% during the 3rd quarter. Cornerstone Investment Partners LLC now owns 344,103 shares of the medical research company’s stock worth $65,359,000 after buying an additional 61,725 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 2.1%

NYSE IQV opened at $182.28 on Thursday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 52 week low of $153.01 and a 52 week high of $247.04. The stock has a market capitalization of $30.42 billion, a PE ratio of 22.59, a price-to-earnings-growth ratio of 1.60 and a beta of 1.21. The firm has a 50 day moving average of $173.18 and a two-hundred day moving average of $194.08.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the previous year, the business posted $2.70 EPS. The firm’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Mizuho set a $215.00 target price on shares of IQVIA in a research note on Monday, February 23rd. Evercore reaffirmed an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. Finally, Morgan Stanley set a $225.00 price target on shares of IQVIA in a report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, IQVIA has a consensus rating of “Buy” and an average target price of $224.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.